ACQUISITIONS and MERGERS

The transaction provides Abbott with a complementary solution for treating vascular disease. CSI’s leading atherectomy system prepares vessels for angioplasty or stenting to restore blood flow.

Gyrus Medical is located in Cardiff, Wales, United Kingdom, is also a device outsourcer, and will increase both ATL’s global footprint and capabilities.

Raymond W. Cohen, chief executive officer of Axonics. “We expect the Radian technology will improve patient comfort, increase physician confidence and SNM access, simplify the learning curve for physicians new to SNM, and increase PNE trial success rates, which should ultimately result in more adults being treated with our life-changing SNM therapy. We are confident that empowering physicians with innovative technology and tools has the potential to drive significant SNM market expansion in the years ahead.”

Novocardia will be the newest division under Cardiovascular Associates of America focusing on the development, testing, and scalability of innovative care models and new value-based and risk-based contracting models that improve quality care and efficiency while lowering costs.

With this acquisition, the consolidated Oxutrx – Spectrum company now has seven (7) process lines, including ISO Optics Lab capabilities, serving medical, commercial and government entities.

Russ Thomas, CEO of Availity. “This technology perfectly aligns with Availity’s vision of delivering omni-channel, multi-payer solutions to a fragmented healthcare data ecosystem. This game-changing solution will help our provider and health plan customers overcome the common barriers to ensuring timely care delivery, resource allocation, and patient satisfaction.”